FSMDX Mutual Fund Forecast & Price Targets

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FSMDX Analyst Rating

Moderate Buy

619 Buy

186 Hold

14 Sell

Based on the consensus analyst ratings on 819 stocks held in FSMDX.

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FSMDX Analyst Price Target

Average Price Target

$41.84

Based on 819 Wall Street analysts offering 12 month price targets to Fidelity Mid Cap Index Fund holdings in the last 3 months. The average price target is $41.84 with a high forecast of $48.71 and a low forecast of $34.80. The average price target represents a 12.96% change from the last price of $37.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"$31","40":"$40","49":"$49","35.5":"$35.5","44.5":"$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48.707,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.841,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.804,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,35.5,40,44.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.63,37.559000000000005,38.488,39.417,40.346000000000004,41.275000000000006,42.204,43.133,44.062,44.991,45.92,46.849000000000004,47.778,{"y":48.707,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.63,37.030846153846156,37.43169230769231,37.83253846153846,38.233384615384615,38.63423076923077,39.03507692307693,39.43592307692308,39.836769230769235,40.23761538461539,40.63846153846154,41.039307692307695,41.44015384615385,{"y":41.841,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.63,36.489538461538466,36.34907692307693,36.208615384615385,36.06815384615385,35.92769230769231,35.787230769230774,35.64676923076923,35.50630769230769,35.36584615384616,35.22538461538462,35.084923076923076,34.94446153846154,{"y":34.804,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.99,"date":1725321600000,"info":"<div>Price: <b>$33<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.09,"date":1727740800000,"info":"<div>Price: <b>$34<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.12,"date":1730419200000,"info":"<div>Price: <b>$34<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":37.03,"date":1733097600000,"info":"<div>Price: <b>$37<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.75,"date":1735776000000,"info":"<div>Price: <b>$34<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.95,"date":1738540800000,"info":"<div>Price: <b>$35<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.67,"date":1740960000000,"info":"<div>Price: <b>$34<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.74,"date":1743465600000,"info":"<div>Price: <b>$33<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.3,"date":1746057600000,"info":"<div>Price: <b>$32<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.15,"date":1748822400000,"info":"<div>Price: <b>$34<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35.56,"date":1751328000000,"info":"<div>Price: <b>$36<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35.47,"date":1754006400000,"info":"<div>Price: <b>$35<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":36.63,"date":1756771200000,"info":"<div>Price: <b>$37<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$48.71

Average Price Target$41.84

Lowest Price Target$34.80

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

FSMDX Stocks With Highest Upside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

VKTX

Viking Therapeutics

―

16 Buy

2 Hold

0 Sell

Strong Buy

―

xxxxxxxxxxxxxxxxxxxxxxxxxxx

RARE

Ultragenyx Pharmaceutical, Inc.

―

16 Buy

1 Hold

0 Sell

Strong Buy

―

xxxxxxxxxxxxxxxxxxxxxxxxxxx

AUR

Aurora Innovation, Inc.

―

4 Buy

2 Hold

0 Sell

Moderate Buy

―

xxxxxxxxxxxxxxxxxxxxxxxxxxx

Loews

―

1 Buy

0 Hold

0 Sell

Moderate Buy

―

xxxxxxxxxxxxxxxxxxxxxxxxxxx

INSP

Inspire Medical

―

8 Buy

8 Hold

0 Sell

Moderate Buy

―

FSMDX Stocks With Highest Downside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

GME

GameStop Corp

―

0 Buy

0 Hold

1 Sell

Moderate Sell

―

xxxxxxxxxxxxxxxxxxxxxxxxxxx

Quantumscape Corporation

―

1 Buy

2 Hold

1 Sell

Hold

―

xxxxxxxxxxxxxxxxxxxxxxxxxxx

DDS

Dillard's

―

0 Buy

1 Hold

2 Sell

Moderate Sell

―

xxxxxxxxxxxxxxxxxxxxxxxxxxx

Ubiquiti Networks Inc

―

1 Buy

0 Hold

1 Sell

Hold

―

xxxxxxxxxxxxxxxxxxxxxxxxxxx

RKT

Rocket Companies Inc

―

0 Buy

7 Hold

0 Sell

Hold

―

FSMDX Mutual Fund FAQ

What is FSMDX’s average 12-month price target, according to analysts?

Based on analyst ratings, Fidelity Mid Cap Index Fund’s 12-month average price target is 41.84.

What is FSMDX’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for FSMDX, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FSMDX a Buy, Sell or Hold?

Fidelity Mid Cap Index Fund has a consensus rating of Moderate Buy which is based on 619 buy ratings, 186 hold ratings and 14 sell ratings.

What is Fidelity Mid Cap Index Fund’s price target?

The average price target for Fidelity Mid Cap Index Fund is 41.84. This is based on 819 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $48.71 ,the lowest forecast is $34.80. The average price target represents N/A Increase from the current price of N/A.

What do analysts say about Fidelity Mid Cap Index Fund?

Fidelity Mid Cap Index Fund’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 819 Wall Streets Analysts.

How can I buy shares of FSMDX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing